Navigation Links
ERT Announces New Report by TUFTS Identifying Growth in Adoption of Centralized ECG Services
Date:6/21/2010

PHILADELPHIA, June 21 /PRNewswire-FirstCall/ -- ERT (Nasdaq: ERES), a global provider of technology and services to the pharmaceutical, biotechnology and medical device industries, announced today the availability of a new report, conducted by the Tufts Center for the Study of Drug Development, mapping the growing adoption of centralized ECG (electrocardiogram) services. The industry-wide report measures the current and anticipated adoption levels of centralized ECGs in clinical trials. This document, entitled "Mapping Adoption of Centralized Cardiac Safety Assessment," is available to download from the company's Centralized Cardiac Safety microsite – www.ert.com/ecg.

The new study, supported by an unrestricted grant from ERT, focuses on the use and adoption of digital and electronic ECGs and reports industry perceptions regarding the use of a centralized cardiac safety assessment provider in support of clinical studies. While the study reported only 33% of respondents currently use a centralized ECG approach, 89% of respondents expect the use of centralized ECGs to increase in five years. The significant increase in centralization is anticipated due to regulatory pressures and sponsors' needs to provide high quality data being highlighted as the key factors to drive significant adoption.  

The results confirm that respondents feel that centralized core labs are a valuable way of conducting cardiac safety assessments and most executives that were interviewed believe that 100% of all cardiac safety studies will eventually be handled by centralized providers. Ninety-seven percent of respondents rated central labs as being more accurate, and 90% rated them as being more efficient than a decentralized approach. Despite the reluctance to deviate from using a decentralized approach due to financial concerns, the Tufts report demonstrates that perceptions are changing with 70% of respondents rating the costs of using an ECG core lab to be less than, or equal to, the cost of using paper. The study further highlights integrating data and workflows into a core lab can result in improved patient safety, increased productivity, allow faster database locks, enhanced service, greater satisfaction and potential cost savings, all of which are offered by a centralized approach. The study also examines the challenges of traditional decentralization methods.  

Mike McKelvey, CEO at ERT, comments, "The study by the Tufts Center for the Study of Drug Development highlights the growing adoption of centralization as our sponsors are realizing the need for and benefits of a core ECG laboratory. Currently approximately 33% of clinical trials use a centralized core lab for cardiac safety; we anticipate that this will increase in the short- and long-term. Regulatory pressures and the necessity for better data quality and accuracy at a faster and more efficient speed are stimulating more rapid adoption. With more accurate, higher quality and standardized data at a lower cost, the positive benefits of centralization are now much better understood by industry professionals."

The report, examining how central core laboratories are playing an increasingly important role in cardiac safety during clinical trials, is available to download on www.ert.com/ecg.

For further information on ERT and its technology and services, please email info@ert.com, call +1 215 972 0420 or visit www.ert.com.

For further press information, please contact Fiona Robinson, The Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel, Cheshire, CW4 8AA, United Kingdom. Phone +44 1477 539539, Fax +44 1477 539540, Email ert@scottpr.com.

About ERT

Based in Philadelphia, PA, eResearchTechnology, Inc. (www.ert.com) is a global provider of technology and services to the pharmaceutical, biotechnology and medical device industries.  The Company is a market leader in providing centralized core-diagnostic electrocardiographic (ECG) technology and services to evaluate cardiac safety in clinical development and centralized respiratory technology and services to evaluate pulmonary function efficacy and safety in clinical development.  The Company also provides solutions to streamline the clinical trials process by enabling its customers to automate the collection, analysis, and distribution of ePRO clinical data using multi-mode technology in all phases of clinical development as well as selected medical devices for the clinical trials and healthcare industries.

Statements included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties, which could cause actual results to differ materially from those expressed or implied from such statements.  These risks and uncertainties include, without limitation, the Company's ability to obtain new contracts, variability in size, scope and duration of projects, integration of acquisitions, competitive factors, technological development, market demand, and other factors described in the Company's filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.


'/>"/>
SOURCE ERT
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. United American Healthcare Corporation Announces Acquisition of Pulse Systems, LLC
2. CardioGenics Announces Reverse Stock Split
3. K-V Pharmaceutical Company Announces the Nomination and Appointment of New Independent Member to the Board of Directors
4. Allied Healthcare Announces Litholyme(TM) -- New CO2 Absorbent Used in Anesthesia
5. Novus Scientific Announces the Sales Launch for TIGR™ Matrix Surgical Mesh - Worlds 1st Long-Term Resorbable Synthetic Mesh
6. -- Neurocrine Announces a Second Corporate Collaboration Within Twenty-Four Hours -- Neurocrine Biosciences Announces a Worldwide Collaboration With Boehringer Ingelheim to Research and Develop GPR119 Agonists for Type II Diabetes
7. Kun Run Biotechnology Announces That They Have Obtained the Manufacturing Approval for Entecavir from the China State Food and Drug Administration
8. TechniScan Announces Adding Another Center to Worldwide Clinical Trials for New Breast Imaging System
9. Miltenyi Biotec Announces Release of Viscover(TM) Preclinical Contrast Agents for in vivo Small Animal Imaging
10. Epocal Announces FDA Clearance of Lactate Test
11. Adeona Announces HartLab Expansion Into Microbiology Testing Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Any dentist who ... challenges of the current process. Many of them do not ... the technical difficulties and high laboratory costs involved. And those ... offer it at such a high cost that the majority ... Dr. Parsa Zadeh , founder of Dental ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: RO, ... clearance for its Elecsys BRAHMS PCT (procalcitonin) assay as ... or septic shock. With this clearance, Roche is the ... fully integrated solution for sepsis risk assessment and management. ... bacterial infection and PCT levels in blood can aid ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... to their offering. The ... commercial environment for MedImmune to enter. The US ageing population ... to drive considerable growth for effective anti-influenza medications. The introduction ... considerably, but development is still in its infancy. ...
Breaking Medicine Technology:
(Date:6/27/2016)... California (PRWEB) , ... June 27, 2016 , ... "FCPX ... fully customizable inside of Final Cut Pro X," said Christina Austin - CEO of ... unique style. Final Cut Pro X users can now reveal the media ...
(Date:6/26/2016)... ... 2016 , ... Quality metrics are proliferating in cancer care, and are derived ... eye of the beholder, according to experts who offered insights and commentary in the ... Care. For the full issue, click here . , For the American Society ...
(Date:6/26/2016)... ... June 26, 2016 , ... ... have been diagnosed with endometriosis. These women need a treatment plan to not ... comprehensive approach that can help for preservation of fertility and ultimately achieving a ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency ... named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director ...
(Date:6/24/2016)... Los Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... plastic surgery procedures that most people are unfamiliar with. The article goes on to ... known procedures, but also many of these less common operations such as calf and ...
Breaking Medicine News(10 mins):